Latin America's largest private oncology network, listed on B3 as ONCO3. Subject of a mandatory tender offer CVM imposed on US manager Centaurus in August 2026, under the bylaws' 15% poison pill.
Last 90 days
Oncoclínicas's tender offer got a date and a price: CVM set an October 24 deadline for Centaurus to launch the offer, with Selic adjustment, after the board's unanimous August 25 ruling that triggered the 15% poison pill. Centaurus contests it and maintains a CAM-B3 arbitration filed before the ruling.
Updated October 31, 2026 · 5 verified articles
Market transmission
The stock tracks the mandatory offer's outcome — price, timetable and appeals — plus fundamentals of treatment volumes, payer disputes and leverage.
Explanatory mechanism, not a forecast or recommendation.Oncoclínicas reported in a material fact support from creditors holding 61.6% of about R$ 5.7 billion in claims under its out-of-court restructuring plan, reaching the quorum to seek court approval, according to CNN Brasil and Times Brasil.
A federal court in São Paulo suspended, through an injunction requested by the Josephina III fund linked to Centaurus, the securities regulator decision requiring a tender offer for Oncoclínicas shares, without annulling the decision or ruling on whether the offer is owed, according to Bloomberg Línea and InfoMoney.
Oncoclínicas presented a new out-of-court restructuring plan covering about R$ 5.7 billion in debt, with swaps into new instruments, longer maturities, convertible debentures and payment in shares, according to a material fact reported by Investidor10 and Money Times.
The Oncoclínicas board elected on September 14 Maurício Hasson as chief financial and investor relations officer, replacing Isaac Quintino, who had held the posts on an interim basis since April 24 and leaves the company after the transition, following eight years at the group; Hasson has more than 14 years in CFO roles, worked at Oncoclínicas itself between 2015 and 2016 and comes from investment banking in Brazil and the United States. Bloomberg Línea notes it is the second CFO change in under a year and that the move comes amid the out-of-court restructuring of R$ 5.1 billion in debt, with JPMorgan citing the search for a profile to lead the process.
CVM's board ruled on August 25 that US asset manager Centaurus must launch a tender offer for Oncoclínicas shares, having crossed the 15% poison-pill trigger in the bylaws — reversing the technical staff's view. The deal is valued at over R$6 billion, and ONCO3 shares rose more than 12% the next session.